Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;97(4):631-2.
doi: 10.3324/haematol.2011.057323. Epub 2012 Jan 22.

Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool

Matteo G Della Porta, Ilaria Ambaglio, Marta Ubezio, Erica Travaglino, Cristiana Pascutto, Luca Malcovati

Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool

Matteo G Della Porta et al. Haematologica. 2012 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Probability of overall survival according to ACE-27 risk at diagnosis in all 840 MDS patients (P=0.11). There was no significant difference in cumulative probability of survival between patients with no comorbidity and those with ACE-27 mild risk (P=0.68), or between patients with moderate and severe risk (P=0.11), whereas OS was significantly lower in patients with both moderate and severe risk compared to those without comorbidity (P=0.044 and P=0.019, respectively).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Della Porta MG, Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica. 2009;94(5):602–6. - PMC - PubMed
    1. Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, Lei X, Shan J, Kantarjian HM, Suarez-Almazor ME. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29(16):2240–6. - PMC - PubMed
    1. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL., Jr Prognostic importance of comorbidity in a hospital-based cancer registry. Jama. 2004;291(20):2441–7. - PubMed
    1. Geraci JM, Escalante CP, Freeman JL, Goodwin JS. Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol. 2005;23(30):7399–404. - PMC - PubMed
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. - PubMed

MeSH terms